Bolt Biotherapeutics Inc. (BOLT) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Bolt Biotherapeutics Inc. (NASDAQ: BOLT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $6.36 (-3.34% 1D, market cap $12.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BOLT ranks #593 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BOLT carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HIND (Vyome Holdings Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M) and KTTA (Pasithea Therapeutics Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M). Among the 5-stock peer group, BOLT leads on earnings multiple (N/A) while BOLT leads on capital efficiency (-35.0% ROIC).
Per BOLT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001641281), Bolt Biotherapeutics Inc. generated $7.7M in revenue (+0.1% YoY), -$33.4M in net income, and -$39.9M in free cash flow against $56.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 70% of 52W Range • RSI-14 at 70.6 (OVERBOUGHT (>70))
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While BOLT currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.19) and Max Pain ($6.68) forces dealer call-delta covering toward $8.17.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Bolt Biotherapeutics Inc. (BOLT) dropped -3.34% to $6.36, trading at 70% of its 52-week range ($3.1 – $7.78). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.
Unusual volume in US small-cap stocks: RBNE, SHFS, AARD, XXII and others traded well above 50-day averages, with sharp losses and double-digit gains.
Bolt Biotherapeutics, Inc. (BOLT) M&A Call October 26, 2026 8:30 AM EDTCompany ParticipantsWilliam Quinn - CEO, CFO, President, Secretary &...
Transactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platformPRA-216 is a novel IL-4Rα/TSLP bispecific antibody
Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics (NASDAQ:LUCD)
Prana’s Pipeline Overview and Development MilestonesPrana’s focus is to develop the next generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. The lead program,
Concurrent with the acquisition, Bolt entered into a definitive agreement for a private placement financing to raise $120 million in gross proceeds, for the purchase of 13,995.311 shares of Series D non-voting
Transactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platform PRA-216 is a novel IL-4Rα/TSLP bispecific
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +0.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BOLT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BOLT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Bolt Biotherapeutics Inc. (BOLT) ranks #593 by composite RQD confidence (38/100, grade D-) and #877 by equity capitalization ($12.3M). Within this direct 5-issuer industry benchmark cohort, BOLT leads on earnings valuation at N/A trailing P/E, while BOLT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KTTA currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with BOLT at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BOLT
ACTIVE
Bolt Biotherapeutics Inc. | D- | 38/100 | — | — | -35.0% | -3.34% | $12.3M | Benchmark Subject |
| HIND Vyome Holdings Inc. | E | 29/100 | — | 68.4% | -35.0% | +1.74% | $12.3M | /hind-vs-bolt → |
| KTTA Pasithea Therapeutics Corp. | D- | 40/100 | — | — | -35.0% | -5.95% | $12.3M | /ktta-vs-bolt → |
| BIVI BioVie Inc. (Class A) | E | 32/100 | — | — | -35.0% | -5.48% | $12.0M | /bivi-vs-bolt → |
| LPCN Lipocine Inc. | E | 23/100 | — | — | -35.0% | +0.66% | $12.5M | /lpcn-vs-bolt → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bolt Biotherapeutics Inc. (BOLT) reported GAAP revenue of $7.7M (+0.1% vs. FY2024 revenue of $7.7M , and -2.3% cumulative change since FY2023) , GAAP net income of -$33.4M, operating cash flow of -$39.9M, and free cash flow of -$39.9M (+34.9% YoY). On the balance sheet, BOLT closed FY2025 with $56.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $7.7M | -$33.4M | -$39.9M | -$39.9M | $56.7M | — |
| FY2024 (FY) | 2024-12-31 | $7.7M | -$63.1M | -$61.3M | -$61.3M | $99.6M | — |
| FY2023 (FY) | 2023-12-31 | $7.9M | -$69.2M | -$69.5M | -$69.5M | — | — |
As of 2026-11-02, Bolt Biotherapeutics Inc. (NASDAQ: BOLT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $6.36 (-3.34% 1D, market cap $12.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BOLT ranks #593 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BOLT carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HIND (Vyome Holdings Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M) and KTTA (Pasithea Therapeutics Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M). Among the 5-stock peer group, BOLT leads on earnings multiple (N/A) while BOLT leads on capital efficiency (-35.0% ROIC).
Per BOLT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001641281), Bolt Biotherapeutics Inc. generated $7.7M in revenue (+0.1% YoY), -$33.4M in net income, and -$39.9M in free cash flow against $56.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BOLT last traded at $6.36 (-3.34% on volume of 76,274 shares), positioning the stock +51.79% above its 50-day simple moving average ($4.19) and +41.33% above its 200-day simple moving average ($4.50). Across its 52-week range of $3.10 to $7.78, BOLT sits at the 69.7% percentile with a 14-day RSI of 70.6 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($5.56 to $7.16).
Why BOLT Stock dropped -3.34% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).